EMA to restrict use of alemtuzumab pending review on: May 14, 2019, 04:34:57 pm #1 The concern about stroke risk has prompted the European Medicines Agency to restrict the use of alemtuzumab pending review. From The Lancet (April 27, 2019), "Alemtuzumab to be restricted pending review, says EMA":https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30935-3/fulltext Last Edit: May 14, 2019, 04:37:16 pm by agate Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
